Before you sell to, join or invest in Salarius Pharmaceuticals, Inc.
MentionFox check on Salarius Pharmaceuticals, Inc.: only 1 source on file so far (checked 6 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/salarius-pharmaceuticals-inc-form-d-24000001
Check Salarius Pharmaceuticals, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
What do you want to do about Salarius Pharmaceuticals, Inc.?
Salarius Pharmaceuticals, Inc. filed a Form D with the Securities and Exchange Commission on 2024-12-27.
Salarius Pharmaceuticals, Inc. filed a Form D notice of an exempt securities offering with the SEC on December 27, 2024. Its industry group is Biotechnology. It names Mark Rosenblum (Executive Vice President, Chief Financial Officer), David Arthur (Chief Executive Officer, President), William McVicar (Chairman of Board) (SEC Form D, December 27, 2024).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Salarius Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2024-12-27 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Salarius Pharmaceuticals, Inc.
Free to see. No signup.
More on the people and the money behind Salarius Pharmaceuticals, Inc., from the filings we hold.
Biotechnology raises by companies based in Texas, filed within 90 days of this one, largest first.
Get an email when Salarius Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Salarius Pharmaceuticals, Inc. raises, hires or launches. No email unless you switch it on.
Watch Salarius Pharmaceuticals, Inc. →Get the full cited report on Salarius Pharmaceuticals, Inc.
What the filing shows about Salarius Pharmaceuticals, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Salarius Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Salarius Pharmaceuticals, Inc.'s address as 2540 Holcombe Blvd., Suite X, Houston, TX 77021.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Salarius Pharmaceuticals, Inc. See pricing
Salarius Pharmaceuticals, Inc. is a registered filer with the SEC (CIK 1615219) and has filed since 2023-05-25. 2 filings are on record, the latest on 2024-12-27.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Salarius Pharmaceuticals, Inc.'s Form D of 2024-12-27 names Mark Rosenblum, David Arthur, William McVicar and 5 more as its officers, directors or promoters.
Its new offerings report $6M sold across 1 offering, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 763 filings in Biotechnology, totalled by week.
On the filing as: Executive Officer.
Mark Rosenblum is named as Executive Vice President, Chief Financial Officer on the Form D that Salarius Pharmaceuticals, Inc. filed with the SEC on 27 December 2024, one of 8 people that filing names.
On the filing as: Director, Executive Officer.
David Arthur is named as Chief Executive Officer, President on the Form D that Salarius Pharmaceuticals, Inc. filed with the SEC on 27 December 2024, one of 8 people that filing names.
On the filing as: Director.
William McVicar is named as Chairman of Board on the Form D that Salarius Pharmaceuticals, Inc. filed with the SEC on 27 December 2024, one of 8 people that filing names.
Jonathan Lieber is named as Director on the Form D that Salarius Pharmaceuticals, Inc. filed with the SEC on 27 December 2024, one of 8 people that filing names.
Tess Burleson is named as Director on the Form D that Salarius Pharmaceuticals, Inc. filed with the SEC on 27 December 2024, one of 8 people that filing names.
Arnold Hanish is named as Director on the Form D that Salarius Pharmaceuticals, Inc. filed with the SEC on 27 December 2024, one of 8 people that filing names.
Paul Lammers is named as Director on the Form D that Salarius Pharmaceuticals, Inc. filed with the SEC on 27 December 2024, one of 8 people that filing names.
Bruce McCreedy is named as Director on the Form D that Salarius Pharmaceuticals, Inc. filed with the SEC on 27 December 2024, one of 8 people that filing names.
8 people named on the filing — 2 holding an executive role and 6 as directors only.
Named as of the 2024-12-27 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Salarius Pharmaceuticals, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Salarius Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Salarius Pharmaceuticals, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Salarius Pharmaceuticals, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Salarius Pharmaceuticals, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Salarius Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Houston
https://mentionfox.com/funding/salarius-pharmaceuticals-inc-form-d-24000001